文献速递淋巴瘤

玻璃体视网膜淋巴瘤玻璃体内甲氨蝶呤治疗20年经验

Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience.
PubMed 文献 · Br J Haematol · 2021-04-26

该回顾性研究纳入1997-2018年129例玻璃体视网膜淋巴瘤(VRL)患者,评估玻璃体内甲氨蝶呤(MTX)注射的疗效与安全性。81例VRL患者(134眼)平均接受19次注射,仅需5次即达完全缓解,局部复发2例;结论认为玻璃体内MTX安全有效,较少注射(15次)可能获得相似效果且副作用更少。

要点

  • 玻璃体内MTX注射是VRL安全有效的治疗,平均19次注射,仅5次可达完全缓解。

核心结论

  • 玻璃体内MTX注射是VRL安全有效的治疗。
  • 较少注射(15次)可能获得相似结果且副作用更少。

研究设计与样本

  • 回顾性研究,纳入1997-2018年诊断的129例患者。

主要发现

  • 淋巴瘤累及中枢神经系统和玻璃体视网膜者占49%,仅中枢神经系统占37%,仅玻璃体视网膜占14%。
  • 81例VRL患者(134眼)平均接受19(7)次注射,仅需5(4)次注射达到完全缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vitreo-retinal lymphoma (VRL) is the most common intraocular lymphoma and is highly associated with central nervous system (CNS) lymphoma (CNSL), both posing a therapeutic challenge. We investigated patients' characteristics, efficacy and safety of intravitreal methotrexate (MTX) injections and their outcomes over 20 years. The records of 129 patients diagnosed between 1997 and 2018 were retrospectively reviewed. Lymphoma involved both the CNS and vitreo-retina (49%), solely the CNS (37%) or solely the vitreo-retina (14%). In all, 45·5% of the patients with CNSL either presented with VRL or developed it after a mean (±SE) of 85·7 (7·3) months. In all, 66·0% of the patients diagnosed with VRL either presented with CNSL or developed it after a mean (±SE) 42·6 (7·6) months. The 81 patients with VRL (134 eyes) received a mean (±SD) of 19 (7) injections; however, only 5 (4) injections were needed to reach complete remission. Local recurrence occurred in two of the 81 patients. Overall, 80·2% of eyes had an initial moderate-severe visual loss, and >50% of them improved. Reversible keratopathy was the most prevalent side-effect. A total of 18·5% developed intraocular pressure (IOP) elevation due to angle neovascularisation after 16 injections, which could be reversed with prompt intravitreal injection of bevacizumab. Intravitreal MTX injections are a safe and effective treatment for VRL. Fewer injections (15) may offer similar results with fewer side-effects.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Habot-Wilner Z, Frenkel S, Pe'er J, et al. Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience. Br J Haematol. 2021. PMID: 33900619. doi:10.1111/bjh.17451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。